Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
arts and humanities
Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease
Archives of Neurology, Volume 65, No. 12, Year 2008
Notification
URL copied to clipboard!
Description
Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an ω-3 fatty acid, improves the motor features of Huntington disease. Design: Six-monthmulticenter,randomized,double-blind, placebo-controlled trial followed by a 6-month open-label phase without disclosing initial treatment assignments. Setting: Forty-one research sites in the United States and Canada. Patients: Three hundred sixteen adults with Huntington disease, enriched for a population with shorter trinucleotide (cytosine-adenine-guanine) repeat length expansions. Interventions: Random assignment to placebo or ethyl- EPA, 1 g twice a day, followed by open-label treatment with ethyl-EPA. Main Outcome Measures: Six-month change in the Total Motor Score 4 component of the Unified Huntington’s Disease Rating Scale analyzed for all research participants and those with shorter cytosine-adenineguanine repeat length expansions (< 45). Results: At 6 months, the Total Motor Score 4 point change for patients receiving ethyl-EPA did not differ from that for those receiving placebo. No differences were found in measures of function, cognition, or global impression. Before public disclosure of the 6-month placebo-controlled results, 192 individuals completed the open-label phase. The Total Motor Score 4 change did not worsen for those who received active treatment for 12 continuous months compared with those who received active treatment for only 6 months (2.0-point worsening; P=.02). Conclusion: Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebocontrolled evaluation. © 2008 American Medical Association. All rights reserved.
Authors & Co-Authors
Dorsey, Earl Ray
Unknown Affiliation
Ross, Christopher A.
Unknown Affiliation
Kieburtz, Karl D.
Unknown Affiliation
Marder, Karen
Unknown Affiliation
Rosenblatt, Adam
Unknown Affiliation
Marder, Karen S.
United States, New York
Columbia University Irving Medical Center
Margolis, Russell L.
United States, Baltimore
Johns Hopkins University
Corey-Bloom, Jody P.
United States, La Jolla
University of California, San Diego
Guttman, Mark
Unknown Affiliation
Racette, Brad A.
United States, St. Louis
Washington University in St. Louis
Nance, Martha A.
United States, Minneapolis
Struthers Parkinson's Center
Suchowersky, Oksana
Canada, Calgary
University of Calgary
Como, Peter G.
United States, Rochester
University of Rochester
Geschwind, Michael D.
United States, San Francisco
University of California, San Francisco
Martin, W. R. Wayne
Canada, Edmonton
University of Alberta
Fernandez, Hubert H.
United States, Gainesville
University of Florida
Hunter, Christine B.
United States, Houston
Baylor College of Medicine
Adams, William H.
Unknown Affiliation
Jankovic, Joseph J.
Unknown Affiliation
MacDonald, Marcy E.
Unknown Affiliation
Manku, Mehar Singh
Unknown Affiliation
Mysore, Jayalakshmi Srinidhi
Unknown Affiliation
Tucker, Lynne
Unknown Affiliation
Statistics
Citations: 95
Authors: 23
Affiliations: 32
Identifiers
Doi:
10.1001/archneur.65.12.1582
ISSN:
00039942
Research Areas
Disability
Study Design
Cross Sectional Study
Study Approach
Quantitative